Cornell Pochily Investment Advisors Inc. Has $385,000 Stake in Pfizer Inc. (NYSE:PFE)

Cornell Pochily Investment Advisors Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 12.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 13,357 shares of the biopharmaceutical company’s stock after selling 1,979 shares during the period. Cornell Pochily Investment Advisors Inc.’s holdings in Pfizer were worth $385,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Front Street Capital Management Inc. lifted its holdings in shares of Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after acquiring an additional 215 shares during the period. Graves Light Lenhart Wealth Inc. lifted its position in shares of Pfizer by 1.4% during the second quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock worth $729,000 after purchasing an additional 281 shares in the last quarter. Infrastructure Capital Advisors LLC lifted its position in shares of Pfizer by 5.2% during the second quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 284 shares in the last quarter. Castleview Partners LLC lifted its position in shares of Pfizer by 2.4% during the first quarter. Castleview Partners LLC now owns 12,207 shares of the biopharmaceutical company’s stock worth $498,000 after purchasing an additional 287 shares in the last quarter. Finally, United Bank lifted its position in shares of Pfizer by 0.6% during the first quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock worth $2,416,000 after purchasing an additional 290 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on PFE. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Friday, March 1st. Barclays decreased their price objective on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a report on Thursday, December 14th. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Guggenheim assumed coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Twelve equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, Pfizer currently has an average rating of “Hold” and an average target price of $36.88.

Pfizer Trading Up 0.5 %

NYSE PFE traded up $0.13 during trading hours on Thursday, reaching $27.91. The company’s stock had a trading volume of 8,245,366 shares, compared to its average volume of 43,306,375. The firm has a fifty day simple moving average of $27.47 and a 200-day simple moving average of $29.47. The stock has a market cap of $158.04 billion, a P/E ratio of 77.47, a P/E/G ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.14 EPS. Equities analysts forecast that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.